• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芳烃受体作为雌激素受体阴性乳腺癌化疗的靶点。

The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy.

作者信息

Zhang Shu, Lei Ping, Liu Xinyi, Li Xiangrong, Walker Kelcey, Kotha Leela, Rowlands Craig, Safe Stephen

机构信息

Institute of Biosciences and Technology, Texas A&M Health Science Center, 2121 Holcombe Boulevard, Houston, Texas 77030, USA.

出版信息

Endocr Relat Cancer. 2009 Sep;16(3):835-44. doi: 10.1677/ERC-09-0054. Epub 2009 May 15.

DOI:10.1677/ERC-09-0054
PMID:19447902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2766348/
Abstract

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and the relatively non-toxic selective aryl hydrocarbon receptor (AhR) modulator 6-methyl-1,3,8-trichlorodibenzo-furan (MCDF) induced CYP1A1-dependent ethoxyresorufin O-deethylase activity and inhibited proliferation of seven estrogen receptor (ER) negative breast cancer cell lines. MCDF, TCDD and structurally related 2,3,7,8-tetrachlorodibenzofuran, 1,2,3,7,8-pentachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 3,3',4,4',5-pentachlorobiphenyl induced CYP1A1 and inhibited proliferation of BT-474 and MDA-MB-468 cells. In BT474 and MDA-MB-468 cells transfected with a small inhibitory RNA for the AhR, the antiproliferative activity of the chlorinated aromatic compounds was reversed, whereas for MCDF, only partial reversal was observed, suggesting that this compound acts through both AhR-dependent and AhR-independent pathways in these two cell lines. MCDF also inhibited tumor growth in athymic nude mice in which MDA-MB-468 cells were injected directly into the mammary fat pad. These results suggest that the AhR is a potential drug target for treatment of ER-negative breast cancer.

摘要

2,3,7,8-四氯二苯并-对-二恶英(TCDD)以及相对无毒的选择性芳烃受体(AhR)调节剂6-甲基-1,3,8-三氯二苯并呋喃(MCDF)可诱导CYP1A1依赖性乙氧基异吩恶唑酮O-脱乙基酶活性,并抑制7种雌激素受体(ER)阴性乳腺癌细胞系的增殖。MCDF、TCDD以及结构相关的2,3,7,8-四氯二苯并呋喃、1,2,3,7,8-五氯二苯并-对-二恶英、2,3,4,7,8-五氯二苯并呋喃和3,3',4,4',5-五氯联苯可诱导CYP1A1,并抑制BT-474和MDA-MB-468细胞的增殖。在转染了针对AhR的小干扰RNA的BT474和MDA-MB-468细胞中,氯化芳香化合物的抗增殖活性被逆转,而对于MCDF,仅观察到部分逆转,这表明该化合物在这两种细胞系中通过AhR依赖性和AhR非依赖性途径发挥作用。MCDF还抑制了无胸腺裸鼠的肿瘤生长,在这些裸鼠中,MDA-MB-468细胞被直接注射到乳腺脂肪垫中。这些结果表明,AhR是治疗ER阴性乳腺癌的潜在药物靶点。

相似文献

1
The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy.芳烃受体作为雌激素受体阴性乳腺癌化疗的靶点。
Endocr Relat Cancer. 2009 Sep;16(3):835-44. doi: 10.1677/ERC-09-0054. Epub 2009 May 15.
2
Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.芳基烃受体激动剂诱导 microRNA-335 的表达并抑制雌激素受体阴性乳腺癌细胞的肺转移。
Mol Cancer Ther. 2012 Jan;11(1):108-18. doi: 10.1158/1535-7163.MCT-11-0548. Epub 2011 Oct 27.
3
Lack of antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin's (TCDDs) induction of cytochrome P4501A1 (CYP1A1) by the putative selective aryl hydrocarbon receptor modulator 6-alkyl-1,3,8-trichlorodibenzofuran (6-MCDF) in the mouse hepatoma cell line Hepa-1c1c7.在小鼠肝癌细胞系Hepa-1c1c7中,假定的选择性芳烃受体调节剂6-烷基-1,3,8-三氯二苯并呋喃(6-MCDF)对2,3,7,8-四氯二苯并对二恶英(TCDD)诱导细胞色素P4501A1(CYP1A1)缺乏拮抗作用。
Chem Biol Interact. 2004 Nov 20;150(2):161-70. doi: 10.1016/j.cbi.2004.09.007.
4
Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha.芳烃受体配体6-甲基-1,3,8-三氯二苯并呋喃与雌激素受体α的相互作用。
Cancer Res. 2004 Apr 15;64(8):2889-97. doi: 10.1158/0008-5472.can-03-1770.
5
Aryl hydrocarbon receptor (AHR)-active pharmaceuticals are selective AHR modulators in MDA-MB-468 and BT474 breast cancer cells.芳基烃受体(AHR)活性药物是 MDA-MB-468 和 BT474 乳腺癌细胞中的选择性 AHR 调节剂。
J Pharmacol Exp Ther. 2012 Nov;343(2):333-41. doi: 10.1124/jpet.112.195339. Epub 2012 Aug 9.
6
Estrogen and aryl hydrocarbon receptor expression and crosstalk in human Ishikawa endometrial cancer cells.雌激素与芳烃受体在人子宫内膜癌 Ishikawa 细胞中的表达及相互作用
J Steroid Biochem Mol Biol. 2000 Apr;72(5):197-207. doi: 10.1016/s0960-0760(00)00030-3.
7
Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: role of estrogen receptor status.CYP1A1和CYP1B1的表达取决于人乳腺癌细胞系中的细胞特异性因子:雌激素受体状态的作用。
Carcinogenesis. 1999 Jun;20(6):947-55. doi: 10.1093/carcin/20.6.947.
8
Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation.芳烃受体介导的LNCaP前列腺癌细胞生长抑制及激素诱导的反式激活。
J Steroid Biochem Mol Biol. 2004 Jan;88(1):27-36. doi: 10.1016/j.jsbmb.2003.10.005.
9
Different response of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-sensitive genes in human breast cancer MCF-7 and MDA-MB 231 cells.2,3,7,8-四氯二苯并对二恶英(TCDD)敏感基因在人乳腺癌MCF-7和MDA-MB 231细胞中的不同反应。
Arch Biochem Biophys. 1995 Aug 20;321(2):405-12. doi: 10.1006/abbi.1995.1411.
10
Possible aryl hydrocarbon receptor-independent pathway of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced antiproliferative response in human breast cancer cells.2,3,7,8-四氯二苯并对二恶英诱导人乳腺癌细胞抗增殖反应的可能芳烃受体非依赖途径。
Toxicol Lett. 2012 Jun 20;211(3):257-65. doi: 10.1016/j.toxlet.2012.04.005. Epub 2012 Apr 15.

引用本文的文献

1
Suppression of global protein synthesis and hepatocellular carcinoma cell growth by Benzimidazoisoquinoline, 4,11-Dichloro-BBQ.苯并咪唑异喹啉4,11-二氯-BBQ对整体蛋白质合成及肝癌细胞生长的抑制作用
Biochem Pharmacol. 2025 Jun;236:116896. doi: 10.1016/j.bcp.2025.116896. Epub 2025 Mar 27.
2
Next-generation of BBQ analogues that selectively target breast cancer.新一代选择性靶向乳腺癌的烧烤类似物。
Front Chem. 2024 Jun 21;12:1396105. doi: 10.3389/fchem.2024.1396105. eCollection 2024.
3
The potential of aryl hydrocarbon receptor as receptors for metabolic changes in tumors.芳烃受体作为肿瘤代谢变化受体的潜力。
Front Oncol. 2024 Feb 16;14:1328606. doi: 10.3389/fonc.2024.1328606. eCollection 2024.
4
Aryl hydrocarbon receptor: An emerging player in breast cancer pathogenesis and its potential as a drug target (Review).芳香烃受体:乳腺癌发病机制中的一个新兴参与者及其作为药物靶点的潜力(综述)。
Mol Med Rep. 2024 Jan;29(1). doi: 10.3892/mmr.2023.13134. Epub 2023 Nov 24.
5
Aryl Hydrocarbon Receptor as an Anticancer Target: An Overview of Ten Years Odyssey.芳香烃受体作为抗癌靶点:十年探索历程概述。
Molecules. 2023 May 9;28(10):3978. doi: 10.3390/molecules28103978.
6
Potential Role of Host Microbiome in Areca Nut-Associated Carcinogenesis and Addiction.宿主微生物组在槟榔相关致癌和成瘾中的潜在作用。
Molecules. 2022 Nov 24;27(23):8171. doi: 10.3390/molecules27238171.
7
The Role of the Aryl Hydrocarbon Receptor (AhR) and Its Ligands in Breast Cancer.芳烃受体(AhR)及其配体在乳腺癌中的作用
Cancers (Basel). 2022 Nov 14;14(22):5574. doi: 10.3390/cancers14225574.
8
Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies.乳腺癌中的表观遗传学与环境:抗癌治疗的新范式
Front Oncol. 2022 Sep 15;12:971288. doi: 10.3389/fonc.2022.971288. eCollection 2022.
9
Amino alcohol acrylonitriles as broad spectrum and tumour selective cytotoxic agents.氨基醇丙烯腈作为广谱且具有肿瘤选择性的细胞毒性剂。
RSC Med Chem. 2021 Mar 9;12(6):929-942. doi: 10.1039/d1md00021g. eCollection 2021 Jun 23.
10
A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway.一种新型萘酰亚胺通过芳香烃受体途径选择性靶向乳腺癌。
Sci Rep. 2020 Aug 19;10(1):13978. doi: 10.1038/s41598-020-70597-8.

本文引用的文献

1
Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells.芳烃受体调节信号转导和转录激活因子1(Stat1)的激活,并参与辅助性T细胞17(Th17)细胞的发育。
Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9721-6. doi: 10.1073/pnas.0804231105. Epub 2008 Jul 7.
2
Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor.芳烃受体对调节性T细胞和辅助性T细胞17分化的调控
Nature. 2008 May 1;453(7191):65-71. doi: 10.1038/nature06880. Epub 2008 Mar 23.
3
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins.芳烃受体将TH17细胞介导的自身免疫与环境毒素联系起来。
Nature. 2008 May 1;453(7191):106-9. doi: 10.1038/nature06881. Epub 2008 Mar 23.
4
Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound.芳烃受体的激活对于介导一种新型低分子量化合物的抗炎作用至关重要。
Blood. 2008 Aug 15;112(4):1158-65. doi: 10.1182/blood-2007-08-109645. Epub 2008 Feb 12.
5
Advances in the treatment of breast cancer.乳腺癌治疗的进展
Clin Pharmacol Ther. 2008 Jan;83(1):26-36. doi: 10.1038/sj.clpt.6100449. Epub 2007 Dec 19.
6
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.绝经后雌激素受体阳性乳腺癌患者中一线内分泌治疗与化疗的2期随机试验。
Cancer. 2007 Jul 15;110(2):244-54. doi: 10.1002/cncr.22789.
7
Neoadjuvant use of endocrine therapy in breast cancer.内分泌治疗在乳腺癌中的新辅助应用。
Breast J. 2007 May-Jun;13(3):243-50. doi: 10.1111/j.1524-4741.2007.00417.x.
8
Dioxin receptor is a ligand-dependent E3 ubiquitin ligase.二噁英受体是一种配体依赖性E3泛素连接酶。
Nature. 2007 Mar 29;446(7135):562-6. doi: 10.1038/nature05683.
9
Progress and new standards of care in the management of HER-2 positive breast cancer.HER-2阳性乳腺癌治疗的进展与新护理标准
Eur J Cancer. 2007 Feb;43(3):497-509. doi: 10.1016/j.ejca.2006.10.020. Epub 2007 Jan 12.
10
The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds.2005年世界卫生组织对二噁英及二噁英类化合物的人类和哺乳动物毒性当量因子的重新评估。
Toxicol Sci. 2006 Oct;93(2):223-41. doi: 10.1093/toxsci/kfl055. Epub 2006 Jul 7.